Basic information |
Metabolite name | L-Histidine |
HMDB0000177 | |
C00135 | |
6274 | |
Synonyms | Histidine |
No. of studies | 31 |
Relationship between L-Histidine and depression (count: 31) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Down |
Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Up |
Study M1140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
Study M475 | Type1 | dHB group vs. HB group | Urine | Human | Up |
Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
Study M545 | Type1 | LPS group vs. control group | Skeletal muscle | C57BL/6 mouse | Up |
Study M545 | Type2 | LPS + ketamine group vs. LPS group | Skeletal muscle | C57BL/6 mouse | Down |
Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
Study M630 | Type2 | acupuncture + antidepressant group, post vs. before treatment | Urine | Human | Up |
Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Up |
Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
Study M875 | Type1 | MDD group vs. control group | Serum | Human | Down |
Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Up |
Study M909 | Type3 | ketamine group vs. control group | Hypothalamus | CD-1 mouse | Up |
Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |